AIM ImmunoTech Files Provisional Patent Application for Ampligen as an Early-Onset Intranasal Therapy that May Also Confer Enhanced Immunity to a Wide Range of Respiratory Viruses
OCALA, Fla., Sept. 27, 2021 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) today…
The Modern Data Company Launches Dex, Conversational AI That Knows When It Has the Answer and Admits When It Doesn’t
Keeping the Business Running While IT Recovers: A Practical Continuity Guide
Helport AI Advances Transition to Autonomous AI Labor in Southeast Asian Fintech Market